Jorge J De La Chapa1, Prajjal Kanti Singha2, Debbie R Lee1, Cara B Gonzales1,3. 1. Department of Comprehensive Dentistry, University of Texas Health Science Center at San Antonio School of Dentistry, San Antonio, TX, USA. 2. Department of Pathology, University of Texas Health Science Center at San Antonio School of Medicine, San Antonio, TX, USA. 3. Cancer Therapy & Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Abstract
BACKGROUND: Thymol is a transient receptor potential ankyrin subtype 1 channel, (TRPA1) agonist found in thyme and oregano. Thymol has antioxidant, anti-inflammatory, and antimicrobial properties; thus, thymol is added to many commercially available products including Listerine mouthwash. Thymol is also cytotoxic to HL-60 (acute promyelocytic leukemia) cells in vitro. Therefore, we evaluated the effects of thymol against oral squamous cell carcinoma (OSCC) and its anticancer mechanism-of-action. METHODS: The antiproliferative effects of thymol in OSCC Cal27 cells were determined by MTS assays. Antitumor effects were evaluated in Cal27- and HeLa-derived mouse xenografts. Calcium imaging, mitochondrial transmembrane potential (ΔΨm) studies, and Western blot analysis of cleaved PARP (c-PARP) evaluated thymol's mechanism-of-action. RESULTS: Thymol had significant, long-lasting antiproliferative effects in vitro. In vivo, thymol displayed significant antitumor effects in Cal27-derived tumors. Thymol's anticancer effects were confirmed in HeLa-derived xenografts demonstrating that thymol effects are not tumor-type specific. Calcium imaging verified calcium influx in Cal27 cells that were reversed with the TRPA1 antagonist, HC030031. However, no calcium influx was seen in HeLa cells indicating that TRP channels do not regulate thymol cytotoxicity. This was confirmed using cell viability assays in which pre-treatment with HC030031 had no effect on thymol cytotoxicity. Instead, ΔΨm studies revealed that thymol induces significant ΔΨm depolarization and apoptosis. CONCLUSION: Our findings provide the first evidence of thymol's novel antitumor effects against OSCC in vivo, which do not rely on TRPA1 activity. Instead, we show that thymol induces mitochondrial dysfunction and apoptosis and may be efficacious against multiple cancers.
BACKGROUND:Thymol is a transient receptor potential ankyrin subtype 1 channel, (TRPA1) agonist found in thyme and oregano. Thymol has antioxidant, anti-inflammatory, and antimicrobial properties; thus, thymol is added to many commercially available products including Listerine mouthwash. Thymol is also cytotoxic to HL-60 (acute promyelocytic leukemia) cells in vitro. Therefore, we evaluated the effects of thymol against oral squamous cell carcinoma (OSCC) and its anticancer mechanism-of-action. METHODS: The antiproliferative effects of thymol in OSCC Cal27 cells were determined by MTS assays. Antitumor effects were evaluated in Cal27- and HeLa-derived mouse xenografts. Calcium imaging, mitochondrial transmembrane potential (ΔΨm) studies, and Western blot analysis of cleaved PARP (c-PARP) evaluated thymol's mechanism-of-action. RESULTS:Thymol had significant, long-lasting antiproliferative effects in vitro. In vivo, thymol displayed significant antitumor effects in Cal27-derived tumors. Thymol's anticancer effects were confirmed in HeLa-derived xenografts demonstrating that thymol effects are not tumor-type specific. Calcium imaging verified calcium influx in Cal27 cells that were reversed with the TRPA1 antagonist, HC030031. However, no calcium influx was seen in HeLa cells indicating that TRP channels do not regulate thymolcytotoxicity. This was confirmed using cell viability assays in which pre-treatment with HC030031 had no effect on thymolcytotoxicity. Instead, ΔΨm studies revealed that thymol induces significant ΔΨm depolarization and apoptosis. CONCLUSION: Our findings provide the first evidence of thymol's novel antitumor effects against OSCC in vivo, which do not rely on TRPA1 activity. Instead, we show that thymol induces mitochondrial dysfunction and apoptosis and may be efficacious against multiple cancers.
Authors: Maria G Sanchez; Ana M Sanchez; Beatriz Collado; Sophie Malagarie-Cazenave; Nuria Olea; Maria J Carmena; Juan C Prieto; Ines Diaz-Laviada I Journal: Eur J Pharmacol Date: 2005-05-16 Impact factor: 4.432
Authors: Lisa Rooney; Agnès Vidal; Anne-Marie D'Souza; Nick Devereux; Brian Masick; Valerie Boissel; Ryan West; Victoria Head; Rowan Stringer; Jianmin Lao; Matt J Petrus; Ardem Patapoutian; Mark Nash; Natalie Stoakley; Moh Panesar; J Martin Verkuyl; Andrew M Schumacher; H Michael Petrassi; David C Tully Journal: J Med Chem Date: 2014-06-13 Impact factor: 7.446
Authors: Jorge J De La Chapa; Prajjal K Singha; Kristen K Self; McKay L Sallaway; Stanton F McHardy; Matthew J Hart; Howard Stan McGuff; Matthew C Valdez; Francisco Ruiz; Srikanth R Polusani; Cara B Gonzales Journal: J Oral Pathol Med Date: 2019-04-04 Impact factor: 4.253
Authors: Sareh Kamran; Ajantha Sinniah; Mahfoudh A M Abdulghani; Mohammed Abdullah Alshawsh Journal: Cancers (Basel) Date: 2022-02-22 Impact factor: 6.639